FDA Approves Abemaciclib for HR+/HER2- Advanced Breast Cancer

On February 26, 2018, the U.S. Food and Drug Administration FDA) approved abemaciclib (Verzenio™, Eli Lilly and Company) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Read FDA announcement.

Posted 2/27/2018